TEACH Summer School
Cascais, Portugal
3-7 July, 2016

Training and Education for Advanced Clinicians and HCPs in Personalised Medicine
Objectives

There are many ways to refer to the core topic of EAPM’s education Summer School, such as personalised medicine, precision medicine, individualised medicine or, if you prefer, stratified medicine.

For the benefit of commonality, the ground-breaking summer school will be centered around the concept of personalised medicine and, for its purposes, this refers to innovative medical interventions tailored to the specific needs of individual patients, thus providing better treatment and preventing undesirable adverse reactions while fostering a more efficient and cost-effective healthcare system.

Personalised medicine starts with the patient. It hold huge potential for improving the health of many patients and ensuring better outcomes of health systems’ efficiency and transparency.

Yet, its integration into clinical practice and daily care is proving difficult given the many barriers and challenges to timely access to targeted healthcare that still exist as of today.

If personalised medicine is to be in line with the EU and Member State principle of universal and equal access to high quality healthcare, then clearly it must be made available to many more citizens than it is now.

Part of what is required is a long-term approach to education to ensure the translation of new therapies from laboratories to patients.

This means that all HCPs in close contact with patients or their patients’ families need to be up-to-date with the current aspects of personalised medicine and its latest breakthroughs in order to better understand their patients’ concerns.

This inaugural summer school aims to support the endeavours of EAPM to set up a Continuous Educational Programme on personalised medicine.

Recognising that the patient is at the centre of his or her own treatment and health-related decisions, the summer school will focus heavily on training in "how to communicate with patients" in several key areas.

EAPM and the faculty at this first summer school are convinced that and improvement in such skills among HCPs is vital to giving the right treatment to the right patient at the right time.

Christine Chomienne, Past President, EHA
Louis Denis, Past President, Europa Uomo

Summer School Co-Chairs
Day One - Sunday 3 July

17:00 - 19:00 Arrival and registration
19:30 - 22:30 Welcome dinner

Day Two - Monday 4 July

Monoclonal antibodies and personalised medicine

Questions addressed by the faculty:

How to target cell surface proteins with a monoclonal antibody? How to kill a cell with a monoclonal antibody? How to enhance or restore a patient’s immune system with monoclonal antibodies? How does one identify a future targetable protein?

08:30 - 09:15 Welcome addresses from the co-chairs of the EAPM Education Summer School

Personalised Medicine: The importance of communicating to patients
Christine Chomienne, Past President, European Hematology Association
Louis Denis, Director Wij Ook/US TOO Belgium

09:15 - 09:30 Patient Literacy and HCP Dialogue
Denis Horgan, EAPM Executive Director

09:30 - 11:00 Plenary Session 1: Monoclonal Antibodies and Targeted Therapies

Session Chair: Peter Riegman, Head of the Erasmus MC Tissue Bank, The Netherlands

09:30 - 10:15 Precision medicine in prevention and early diagnosis of cancer
Angelo Paradiso, IRCCS Foundation - Istituto Tumori Bari

Followed by Q&A

10:15 - 11:00 Monoclonal Antibodies and Solid Tumors
Dr James Spicer, Reader in Experimental Oncology, King’s College London, United Kingdom

Followed by Q&A

11:00 - 11.30 Coffee Break
Day Two - Monday 4 July (continued)

11.30 - 13:00 Plenary Session 2: Communication skills

Session Chair: Steve Johnson, Taunton UK
Followed by Q&A

13:00 - 14:00 Lunch

14:00 - 15:30 Plenary Session 3: Monoclonal antibodies

Session chair: Christine Chomienne, Past President, European Hematology Association

14:00 - 14:45 Monoclonal Antibodies to identify/trigger cell surface targets
Prof. Holger Moch, University Hospital Zurich, Department of Pathology, Switzerland; European Society of Pathology

Followed by Q&A

14:45 - 15:30 Monoclonal Antibodies - setting the scene at the Political Level
Ricardo Bapista, MP, Portuguese Parliament

Followed by Q&A

15:30 - 16:00 Coffee break

16:00 - 18:00 What is the right treatment for me?
Role Play

Facilitator: Steve Johnson, Taunton UK

19:30 - 22:30 Dinner and speech (Patient-Doctor communication)
Angelo Paradiso, IRCCS Foundation - Istituto Tumori Bari

Day Three - Tuesday 5 July

Inhibitory drugs and personalised medicine

Questions addressed by the faculty:

What are protein kinases? Why are they such important to target? How does one identify drug that inhibit protein kinases?

09:00 - 10:30 Plenary Session 4: Inhibitors Part I

Session Chair: Christine Chomienne, Past President, European Hematology Association
Day Three - Tuesday 5 July (continued)

09:00 - 09:45  Systems medicine to individualise treatment for asthma
Ian Adcock, Imperial College London, ERS Assembly Head for Airway Diseases

Followed by Q&A

09:45 - 10:30 Inhibitors in Oncology
Paolo G. Casali, ESMO Public Policy Committee Chair

Followed by Q&A

10:30 - 11:00 Coffee Break

11:00 - 13:00 Plenary Session 5: Communication skills
Session Chair: Steve Johnson, Taunton UK

Followed by Q&A

13:00 - 14:00 Lunch

14:00 - 15:30 Plenary Session 6: Inhibitors Part II
Session Chair: Louis Denis, Director Wij Ook/US TOO Belgium

14:15 – 14:45 A clinical trial with inhibitors
Professor Philippe Rousselot, Service d'hématologie et oncologie, CH de Versailles, Hôpital André Mignot

Followed by Q&A

14:45 – 15:30 Abnormal Tyrosine Kinase inhibitors monitoring
Torsten Haferlach, MLL Leukaemia Labor GmH Munchen

Followed by Q&A

15:30 – 16:00 Coffee break

16:00 - 18:00  Communication with the patient
Role Play

Facilitator: Steve Johnson, Taunton UK

19:30 - 22:30 Dinner and speech ('Patient stories')
Luis Mendao, Chair of the Board of GAT - Treatment Activist Group
Day Four - Wednesday 6 July

Patient at the centre of personalised medicine

Questions addressed by the faculty:

Topics on patient information and consent, data sharing and protection

09:00 - 10:30 Plenary Session 7: Adapt treatment to patient

Session Chair: Christine Chomienne, Past President, European Hematology Association

09:00 - 09:45 Biobanking, patient consent and data ownership
Peter Riegman, Head of the Erasmus MC Tissue Bank, Netherlands

Followed by Q&A

09:45 - 10:30 Health literacy and patient information
Denis Horgan, Executive Director, EAPM
Natacha Bolanos, Spanish Group for Cancer Patients, GEPAC
Silvia Riva, University of Milan, Faculty of Oncology and Hemato-oncology

Followed by Q&A

10:30 - 11:00 Coffee break

11:00 - 13:15 Plenary Session 8: Pharmacogenomics and personalised medicine
Session Chair: Giovanni Codacci Pisanelli, Assistant Professor of Medical Oncology, Rome University

11:00 – 11:45 Clinical utility of genotype-guided Warfarin therapy
Rob Hastings, Senior Manager, Market Development, Illumina

Followed by Q&A

11:45 - 12:30 Personalised medicine and pharmacogenomics
Ron Schaik, Full Professor of Pharmacogenomics and President of ESPT

Followed by Q&A

12:30 - 13:15 Genomics as a tool for precision therapeutics in epilepsy
Gianpiero Cavalleri, RCSI Molecular & Cellular Therapeutics (MCT) Royal College of Surgeons in Ireland

Followed by Q&A

13:15 - 14:00 Lunch

14:00 - 15:30 Free afternoon (optional visit to Cascais)
Day Four - Wednesday 6 July (continued)

17:00 - 18:30 Programme evaluation, identifying gaps and preparation of future training programmes

19:30 - 22:30 Dinner and speech (Patient stories)
Peter Kapitein, Inspire2Live

Day Five - Thursday 7 July

09:00 - 10:30 Plenary Session 9: 'Report from the groups'
Session Chairs: Christine Chomienne, Past President, European Hematology Association
Louis Denis, Director Wij Ook/US TOO Belgium

10:30 - 11:00 Coffee Break and group photographs

11:00 - 12:00 Keynote Speech:
Ken Mastris, President, Europa Uomo

12:00 - 13:00 Lunch
About EAPM

The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.

The aim is to improve patient care by accelerating the development, delivery and uptake of personalised medicine and diagnostics, through consensus.

As the European discussion on personalised medicine gathers pace, EAPM is a response to the need for wider understanding of priorities and a more integrated approach among distinct lay and professional stakeholders.

The mix of EAPM members provides extensive scientific, clinical, caring and training expertise in personalised medicine and diagnostics, across patient groups, academia, health professionals and industry. Relevant departments of the European Commission have observer status, as does the EMA.

EAPM is funded by its members.

Contact: Denis Horgan
EAPM Executive Director
Avenue de l’Armee/Legerlaan 10, 1040 Brussels
Tel: + 32 4725 35 104
Website: www.euapm.eu

Event Sponsors